Stock Info
Company Overview
Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre’s pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23.
Corporate Presentation
Investor Contact
Eric McIntyre
eric.mcintyre@spyre.com
Investor Email Alerts